CRDL Cardiol Therapeutics

EQS-News: Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

EQS-News: Cardiol Therapeutics
Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

16.12.2022 / 18:26 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive Canada

Proactive Canada


News Source: News Direct

16.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Cardiol Therapeutics
United States
ISIN: CA14161Y2006
EQS News ID: 1515789

 
End of News EQS News Service

1515789  16.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1515789&application_name=news&site_id=research_pool
EN
16/12/2022

Underlying

CRDLCardiol Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cardiol Therapeutics

 PRESS RELEASE
Free
CRDL Cardiol Therape...

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genu...

Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference in Boston, MA, on August 12, 2025, at 9:30 a.m. EDT.A live webcast of the Fireside Chat will be accessible under "Events & Presentations" in the Investors section of the Cardiol website (). The repla...

August 11, 2025 1 EN
 PRESS RELEASE
Free
CRDL Cardiol Therape...

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHE...

Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo.Reduction in ECV was associated with improvements across multiple pre-specified cardiac magnetic resonance imaging (CMR) endpoints, including a significant reduction in LV mass.The ARCHER trial results provide compelling clinical proof of concept for CardiolRx™ and strongly support advancing the clinical development of CardiolRx™ and CRD-38 in cardiomyopathies, heart failure, and myocarditis.The ARCHER results have been submitted for pre...

August 6, 2025 1 EN
 PRESS RELEASE
Free
CRDL Cardiol Therape...

Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial...

ARCHER is designed to assess the impact of CardiolRx™ on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis in myocarditis patients.Acute myocarditis is a potentially life-threatening condition affecting the heart muscle (myocardium) and is characterized by chest pain, shortness of breath, fatigue, rapid or irregular heartbeat (arrhythmias), and light-headedness, and can lead to heart failure or sudden cardiac death.There are no FDA-approved drug therapies indicated for the treatment of acute myocarditis.To...

July 22, 2025 1 EN
 PRESS RELEASE
Free
CRDL Cardiol Therape...

Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of...

Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on May 28, 2025. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company's Management Information Circular dated April 10, 2025.Resolutions proposed and approve...

May 29, 2025 1 EN
 PRESS RELEASE
Free
CRDL Cardiol Therape...

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shar...

Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on May 28, 2025, at 4:30 p.m. EDT.Cardiol Therapeutics' 2025 AGMWhen: May 28, 2025, at 4:30 p.m. EDTWhere: Virtual meeting only via live audio webcast online at: Additional information about the AGM, including details ...

May 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch